Ignite Creation Date:
2025-12-25 @ 1:37 AM
Ignite Modification Date:
2026-01-07 @ 4:39 AM
Study NCT ID:
NCT04874194
Status:
TERMINATED
Last Update Posted:
2025-11-03
First Post:
2021-05-01
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
Sponsor:
M.D. Anderson Cancer Center
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
2020-0890
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None